Additional Relevant Details Currently, Genocea just initiated dosing for its Phase 2b testing of GEN-003 for the viral reduction of genital herpes.  The Phase 2b study aims to look at the efficacy of GEN-003 in viral reduction, however the Company will also test potential Phase 3 endpoints by using an improved formula of GEN-003 "manufactured with commercially-scalable process".  Expect the data for Phase 3 endpoints to be released in 2H of 2016, following the viral reduction data release in mid-2016.